MAPT and Alzheimer disease: Furthermore, AD is marked by defects in branched-chain amino acid (BCAA) catabolism, which elevates BCAA levels and promotes tau phosphorylation via an mTOR-dependent mechanism.[3] mTORC2 plays distinct roles in AD pathology.